Ozempic for Men: Evidence, Eligibility, Coverage

Ozempic has no separate rule for men. It is approved for type 2 diabetes, heart risk and kidney disease in type 2 diabetes. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.

Active ingredient: semaglutide
How it is taken: weekly injection
Approved for: Type 2 diabetes, heart risk and kidney disease in type 2 diabetes
Best result (STEP 1): 14.9% weight loss

Ozempic in brief

Time it remains in your body

Its half-life is about 1 week. After 7 d, half is gone, and five half-lives (35 d) leaves about 3% behind.

Main trial weight loss

In SUSTAIN 1, people with type 2 diabetes lost 4.7 kg over 30 weeks, while the placebo group lost 1.2 kg.

Costs over time

Prices each month in US dollars include the list price and self-pay offers, all read from the maker's price website.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Ozempic: who qualifies
Who sets the rule	Who qualifies
FDA label	With diet and exercise as part of the plan, it lowers blood sugar in adults with type 2 diabetes.
FDA label	Heart-related death, heart attack, and stroke become less likely for adults with type 2 diabetes and heart disease.
FDA label	For adults with type 2 diabetes and chronic kidney disease, it lowers the risk of kidney disease getting worse, kidney failure, or heart-related death.
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	first comes a diet and activity program of 6 months

Sources: FDA (DailyMed) label, aetna.com.

Trial results for men

No trial included only men. All participants were adults with obesity or overweight who did not have diabetes.

Trials that used semaglutide, the same ingredient
Trial	Medicine	Who took part	Length	People	Main result	Comparison
STEP 1	Wegovy	Adults with obesity or overweight, without diabetes	68 weeks	1,961	14.9% weight loss	2.4% on placebo
OASIS 4	Wegovy	Adults with obesity or overweight, without diabetes	64 weeks	307	13.6% weight loss	2.4% on placebo

STEP 1 (FDA label (DailyMed)) is the study source.

What is different for men?

Ozempic: label points that matter for men
What changes	What the label says
Risk of Thyroid C-Cell Tumors	It caused thyroid C-cell tumors in rodents. Whether it causes them in people is not known. People with medullary thyroid cancer (MTC) in their own or family medical history should not take it, and neither should people with MEN 2.
Acute Pancreatitis	Can cause inflammation of the pancreas. Stop taking it and get medical care for severe pain in your stomach that does not go away. This pain sometimes spreads to the back.

As stated in the FDA labels: DailyMed FDA label.

The FDA label on DailyMed provides these warnings.

Coverage for men

Medicare Part D does not pay for a GLP-1 when it is used only for weight loss.

Prior authorization is usually part of Medicaid coverage for weight-loss GLP-1s.

Sources: humana.com, KFF.

Alternatives for men

GLP-1 medicines and men
Medicine	For men	How it is taken	Trial result
Ozempic	Approved uses apply	weekly injection	Not listed
Wegovy	Approved uses apply	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Approved uses apply	daily tablet	Not listed
Mounjaro	Approved uses apply	weekly injection	Not listed
Zepbound	Approved uses apply	weekly injection	20.9% weight loss
Foundayo	Approved uses apply	daily tablet	11.1% weight loss
Trulicity	Approved uses apply	weekly injection	Not listed
Saxenda	Approved uses apply	daily injection	7.4% weight loss
Victoza	Approved uses apply	daily injection	Not listed
Byetta	Approved uses apply	twice-daily injection	Not listed